JNJ
JOHNSON & JOHNSON
NYSE · Healthcare · Drug Manufacturers - General · US
$253.96
−0.63%Year over year
Reported trailing growth
- Revenue
- +7.8%
- EBITDA
- -22.1%
- EBIT
- +6.2%
- EPS
- -36.8%
- Free cash flow
- +3.2%
- Operating cash flow
- +1.3%
Forward estimates
Based on analyst estimates
- Revenue
- +6.9%
- EBITDA
- +26.3%
- EPS
- +74.7%
Three-year CAGR
- Revenue
- +5.6%
- EBITDA
- +15.6%
- EBIT
- +6.8%
- Net income
- +14.3%
- EPS
- +17.3%
- Free cash flow
- +4.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026